Table 3

LA and aCL isotype distribution in aPL-positive patients developing thrombosis or not*

ParameterAPS–RSA group without thrombosis (n=46)APS–RSA group and thrombosis (n=11)aPL group (n=30)
aCL26 (56%)5 (46%)20 (67%)
 aCL IgM5 (19%)0 (0%)4 (20%)
 aCL IgG15 (58%)3 (60%)12 (60%)
 aCL IgM + IgG6 (23%)2 (40%)4 (20%)
LA11 (24%)3 (27%)7 (23%)
aCL + LA9 (20%)3 (27%)3 (10%)
 aCL IgM + LAC3 (33%)1 (33%)0 (0%)
 aCL IgG + LAC5 (56%)2 (67%)3 (100%)
 aCL IgG + IgM + LAC1 (11%)0 (0%)0 (0%)
  • Values are n (%).

  • * p Value: NS (by χ2 test).

  • aCL, anticardiolipin antibodies; aPL group, patients with positive tests for antiphospholipid antibodies (aPL) without pregnancy or thrombotic morbidity; APS–RSA group, antiphospholipid syndrome patients with recurrent spontaneous abortion; IgG, immunoglobulin G; IgM, immunoglobulin M; LA, lupus anticoagulant.